We read with great interest the case series by Zhu et al [@bib0005]. We applaud their commitment to their patients in these difficult times. However, we feel that some questions remain unanswered. Did the authors check for the presence of bacterial and/ or fungal co-infection in sputum, as has been commonly seen in patients with COVID-19infection [@bib0010]? Such co-infections may have contributed to the respiratory symptoms, especially in case of the transplant patients. Tian et al [@bib0015] recently reported on the presence of superimposed bacterial bronchopneumonia in post-mortem lung biopsy specimens from COVID-19 patient.

The authors should also report the criteria for starting and stopping IVIG, since we noticed that patient number 7, who had mild disease, received IVIG, but patients 3 and 8, who had critical disease, did not receive IVIG. We noted that patients 2 and 9 had several comorbidities and experienced a severe clinical course. Yang et al [@bib0010] recently reported a severe clinical course and higher mortality among nontransplant patients with comorbidities such as cardiovascular disease and diabetes mellitus, so how can the authors be sure that the severe course of COVID-19 in their transplant patients was entirely due to immunosuppression, especially as we have no data regarding comorbidities in the control group for comparison? Diabetic nephropathy is the second leading cause of end-stage renal disease in China after primary glomerulonephritis [@bib0020], so it is surprising to see that none of the patients in the current series were diabetic. We would urge the authors to check the diabetic status of their patients, as diabetes was noted among 22% of the patients who died in one study, versus 10% among the survivors [@bib0010].

We feel that answers to the above-mentioned queries will help us to better understand the clinical course of COVID-19 infection in renal transplant patients. This type of study on a larger scale with the above-mentioned questions answered might help us to better understand the contribution of comorbidities and immunosuppression individually towards the severity of this disease.

We would like to conclude by thanking the authors for sharing their knowledge and contributing towards the collective scientific effort and knowledge.
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